Implantable Cardioverter Defibrillator (ICD) Market size is forecast to reach $7.92 billion by 2024, growing at a CAGR of 2.53% during the forecast period 2019-2024. Increasing prevalence of cardiac arrhythmias and technological advances such as the development of MRI safe ICDs are the factors driving the growth of the market. Rising number of training and awareness programs on defibrillators will further enhance the overall market demand of implantable cardioverter defibrillator during the forecast period.
- North America dominates the implantable cardioverter defibrillator market owing to increasing prevalence of cardiac diseases and favorable reimbursement policies.
- The growing aging population for cardiovascular diseases and rising awareness about advantages of ICD Devices is likely to aid in the market growth of implantable cardioverter defibrillator market.
- Detailed analysis on the Strength, Weakness and opportunities of the prominent players operating in the market will be provided in the implantable cardioverter defibrillator report.
- High cost associated with the device and lack of skilled professionals will create hurdles for the implantable cardioverter defibrillator market.
Product Type – Segment Analysis
Cardiac Resynchronization Therapy Defibrillator (CRT-D) held the largest share in the implantable cardioverter defibrillator market in 2018 and will grow at a CAGR of 2.2% during the forecast period 2019-2024. This is mainly owing to the factors such as these devices are small in size and are easily placed under the collar bone to improve heart rhythm. These features has propelled the demand for CRT-D devices. Implantable cardioverter defibrillator treatment consists of defibrillation especially ventricular fibrillation. Ventricular tachycardia and atrial fibrillation are the general symptoms. However, Subcutaneous Implantable Cardioverter Defibrillators (S-ICDS) is estimated to be the fastest growing segment and will register a higher CAGR during the forecast period 2019-2024. This is mainly on account of their large size and greater battery capacity.
End Users – Segment Analysis
Hospitals holds a major share in the implantable cardioverter defibrillator market in 2018 and is estimated to grow at a CAGR of 3.6% during the forecast period 2019-2024. Hospitals are well equipped with ICD devices and automated ICDs. The support from the government policies for the adoption of ICD devices in the hospitals will help in the growth of this segment. Moreover, ambulatory surgical centers is estimated to be the fastest growing segment and will register a higher CAGR during the forecast period 2019-2024, owing to the rising cases of sudden cardiac arrest at out of hospital settings and increasing number of public access defibrillation programs across the globe.
Geography – Segment Analysis
North America dominated the implantable cardioverter defibrillator market with a share of more than 34.6%, followed by Europe. The growing prevalence of cardiac diseases is resulting in the high adoption of ICD devices. Rising awareness about advantages of ICD Devices and introduction of favorable reimbursement guidelines by the government will also help to foster the growth of market in this region. Increasing number of public defibrillation programs and availability of large number of healthcare professionals will help in the growth of the market in the Europe region
However, Asia-Pacific is estimated to grow at a higher CAGR during the forecast period. This is so because of the growing aging populations in countries such as Japan, China and increasing awareness among physicians and healthcare professionals about implantable cardioverter defibrillator. The increasing cases of cardiovascular diseases and improving research infrastructure along with rising disposable incomes will support the growth of the market in this region.
Drivers – Implantable Cardioverter Defibrillator Market
- Rising prevalence for cardiovascular disorders
The growing pool of patients who are suffering from cardiovascular disease is one of the key factors augmenting the growth of implantable cardioverter defibrillator market. The rising prevalence of cardiac arrhythmias will increase the demand for cardiac implants, which will fuel the growth of the implantable cardioverter defibrillator (ICD) market during the forecast period.
- Technological Advancements in Defibrillators and Increasing training programs.
Rising technological advancements and the development of MRI safe ICDs, improvements in patient monitoring to avoid needless shocks, and the introduction of quadripolar lead devices have significantly improved the reliability and effectiveness of ICDs. Companies are introducing advanced features in ICDs to reduce the incidence of shocks. There are several training workshops for patients as well as for the surgeons regarding the implantable cardioverter defibrillator devices organized by various manufacturers of implantable cardioverter defibrillator devices which has also led to the increase in the awareness amongst the surgeon and the patients.
Challenges – Implantable Cardioverter Defibrillator Market
- High cost of devices & unfavorable reimbursement policies
High cost associated with implantable cardioverter defibrillator in developing and under-developed countries has resulted in inadequate adoption in healthcare facilities. Lack of training or skilled professionals to operate and worries about its safety among different population groups may hamper the growth of the Implantable cardioverter defibrillator market over the forecast period. Unfavorable reimbursement policies in different regions of the world can also act as restrain to the market.
Implantable Cardioverter Defibrillator Industry Outlook:
Product launches, acquisitions and R&D activities are key strategies adopted by players in the Implantable Cardioverter Defibrillator industry. In 2018, the implantable cardioverter defibrillator share is consolidated by the top five players. Implantable Cardioverter Defibrillator top 10 companies present in the market are Boston Scientific Corporation, LivaNova PLC Company, Imricor Medical Systems, MicroPort Scientific Corporation, Mayo Clinic US, Medtronic plc, MRI Interventions, Inc., St. Jude Medical, Inc., among others.
- In September, 2017, Boston Scientific Corp. launched the Resonate family of implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) systems featuring the HeartLogic Heart Failure Diagnostic to help physicians improve heart failure (HF) management.
- In October 2019, Medtronic plc announced the start of a worldwide pivotal study evaluating its investigational Extravascular Implantable Cardioverter Defibrillator (EV ICD) system to treat dangerously fast heart rhythms.
IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications market research. Our Custom Research Services are designed to provide insights on the constant flux in the global supply-demand gap of markets. Our strong team of analysts enables us to meet the client research needs at a rapid speed, with a variety of options for your business. Any other custom requirements can be discussed with our team, drop an e-mail to email@example.com to discuss more about our consulting services.